Fate Therapeutics, Inc. (FATE) — Analysis Summary
Fate Therapeutics, Inc. (FATE) has a market cap of $291.16M with year-over-year revenue growth of -51.2%. Net margin stands at -2051.1%. The stock trades at a P/E ratio of -2.3.
Key Takeaways
- Revenue changed -51.2% year-over-year
- Net margin of -2051.1%
- P/E ratio of -2.3
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, FATE posted revenue growth of -51.2% and trades at a P/E of -2.3.
Fate Therapeutics, Inc. (FATE)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -2058.1% — severe operating losses
Net margin at -1941.1% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
161
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.